Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II study of ONO-4538 in patients with relapsed or metastatic malignant melanoma

Trial Profile

A Phase II study of ONO-4538 in patients with relapsed or metastatic malignant melanoma

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Nov 2018

At a glance

  • Drugs Nivolumab (Primary)
  • Indications Malignant melanoma
  • Focus Therapeutic Use
  • Sponsors Ono Pharmaceutical
  • Most Recent Events

    • 01 Nov 2018 Results evaluating risk factors and the clinical course of Thyroid Disfunction induced by nivolumab ONO-4538-01, ONO-4538-02, ONO-4538-04, ONO-4538-05, ONO-4538-06, and ONO-4538-08, published in the Cancer Science.
    • 19 Oct 2018 Results of a pooled population pharmacokinetics and exposure-safety analysis from 9 studies, published in the Journal of Clinical Pharmacology.
    • 25 Nov 2016 Status changed from active, no longer recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top